Company
Boehringer Ingelheim
7 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers; 2 in phase 3.
Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.
Biomarkers
Drugs in these trials
Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).
zongertinib 5pembrolizumab 3BI 1701963 2atezolizumab 1durvalumab 1nivolumab 1trametinib 1
Upcoming readouts
Active phase 2 and 3 trials whose primary completion date falls in the next 12 months, according to the sponsor.
- 2026-12 Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment Phase 3 · HER2 (ERBB2) activating mutation
- 2027-08 Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab Phase 2 · HER2 (ERBB2) activating mutation
Trials
7 of 29 trials shown
-
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
zongertinib FDApembrolizumabatezolizumabdurvalumabnivolumab
HER2 mutation: Documented Tyrosine kinase domain (TKD) activating Human epidermal growth factor recepto…
HER2 (ERBB2) activating mutationNon-small Cell Lung Cancer
-
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
zongertinib FDApembrolizumabcisplatincarboplatinpemetrexed
Documented Human epidermal growth factor receptor 2 (HER2) mutation in the Tyrosine kinase domain (TKD) as per local lab results.
HER2 (ERBB2) activating mutationLung Cancer, Non-squamous, Non-small Cell
-
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
zongertinib FDAcisplatincarboplatinpemetrexedpembrolizumab
Documented activating human epidermal growth factor receptor 2 (HER2) mutation as per existing local lab result
HER2 (ERBB2) activating mutationLung Cancer, Non-squamous, Non-small Cell
-
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
zongertinib FDA
…ented Human epidermal growth factor receptor 2 (HER2)-positive status or known activating HER2 mutations (by local testing)
HER2 (ERBB2) activating mutationSolid Tumours
-
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
BI 1823911BI 1701963midazolam
KRAS mutation status: Kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation in tumour tissue or blood based on previously performed local testing using a v…
KRAS G12CKRAS G12DSolid Tumors, KRAS Mutation
-
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
zongertinib FDA
…ll lung cancer (NSCLC) patients with documented human epidermal growth factor receptor 2 (HER2) mutation in the tyrosine kinase domain (TKD) as per local lab results.
HER2 (ERBB2) activating mutationNeoplasm Metastasis, Non-Small Cell Lung Cancer
-
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)
Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening
KRAS G12CKRAS G12DSolid Tumors, KRAS Mutation; SOS1
-
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)
afatinib FDA EU
Evidence of common EGFR activating mutations (Del 19 and/or L858R)
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, ErbB Receptors
-
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
afatinib FDA EU
Evidence of common EGFR mutation (Del 19 and/or L858R)
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, ErbB Receptors
-
Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
afatinib FDA EU
…ly Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer
BI 695502bevacizumab
…g epidermal growth factor receptor (EGFR) / anaplastic lymphoma receptor tyrosine kinase (ALK) mutation maybe included provided chemotherapy is standard of care.
ALK fusionCarcinoma, Non-Small-Cell Lung
-
Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations
afatinib FDA EU
Epidermal Growth Factor Receptor (EGFR) mutation-positive results per the institution's testing methodology
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
afatinib FDA EU
Epidermal Growth Factor Receptor (EGFR) mutation-positive result per the institution's testing methodology.
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
afatinib FDA EU
presence of Epidermal Growth Factor Receptor (EGFR) mutations in tumor biopsy
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
gemcitabinecisplatinafatinib FDA EU
…ine Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, Adenocarcinoma
-
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
pemetrexedafatinib FDA EUcisplatin
…ine Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung, Adenocarcinoma
-
Afatinib in NSCLC With HER2 Mutation
afatinibpaclitaxel
Tumor tissue with HER2 mutations as confirmed by AmoyDx® HER2 Mutation Detection Kit
HER2 (ERBB2) activating mutationCarcinoma, Non-Small-Cell Lung
-
LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung
afatinib FDA EUgefitinib FDA EU
Documented activating epidermal growth factor receptor mutation (Del19 and/or L858R) with tumour tissues.
EGFR exon 19 deletion / L858RLung Neoplasms
-
Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.
afatinib FDA EU
… and/or HER2 gene amplification by FISH testing or patients with tumors that harbor known activating EGFR mutations.
EGFR exon 19 deletion / L858RNeoplasms
-
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
afatinib FDA EU
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive)
BI 3011441
…AS viral (v-ras) oncogene homolog (NRAS) or Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation based on local test.
KRAS G12CKRAS G12DSolid Tumors, KRAS Mutation
-
A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])
BI 1701963BI 3011441
Previously-identified activating Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation in tumour tissue or blood prior to screening.
KRAS G12CKRAS G12DSolid Tumors, KRAS Mutation
-
A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutation
BI 1701963irinotecan
Patient must have a confirmed activating KRAS mutation in CRC tumour tissue by local test.
KRAS G12CKRAS G12DMetastatic Colorectal Cancer (CRC)
-
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Xentuzumababemaciclibletrozoleanastrozolefulvestrant
…anaplastic lymphoma kinase (ALK) inhibitors is mandatory in participants whose tumour has EGFR-activating mutations or ALK translocations.
EGFR exon 19 deletion / L858RALK fusionNeoplasms, Breast Neoplasms
-
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
EzabenlimabBI 754111
…Tumour mutational burden (TMB) (≥10 mutations/Mb) and/or Microsatellite instability high (MSI-H) and/or DNA MMRd solid tumours
MSI-H / dMMRNeoplasms, Carcinoma, Non-Small-Cell Lung
-
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Xentuzumabafatinib FDA EU
Activating EGFR mutation (exon 19 deletion, L858R, G719X, L861X)
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
Monotherapy Dose Finding With BI 847325 in Solid Tumours
day 1 to day 5day 1 to day 14
…rine pancreas adenocarcinoma, and have been shown on their archival tumour sample to have KRAS or BRAF mutation.
KRAS G12CKRAS G12DBRAF V600ENeoplasms
-
Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer
…ctor Receptor (EGFR) -mutation known to be associated with drug sensitivity (i.e., G719X, exon 19 deletion, L858R, L861Q) from previous tumor biopsy or surgery.
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
-
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
afatinib FDA EUSirolimus (rapamycin)
are EGFR mutation-positive or
EGFR exon 19 deletion / L858RCarcinoma, Non-Small-Cell Lung
No trials match these filters.